Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. ERG Controls B Cell Development by Promoting Igh V-to-DJ Recombination

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Single mRNP Analysis Reveals that Small Cytoplasmic mRNP Granules Represent mRNA Singletons

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Nodal Signaling Regulates Germ Cell Development and Establishment of Seminiferous Cords in the Human Fetal Testis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Gamma-Aminobutyric Acid Signaling in Brown Adipose Tissue Promotes Systemic Metabolic Derangement in Obesity

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Genome-wide association study of circulating levels of glucagon during an oral glucose tolerance test

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The renal extraction and the natriuretic action of GLP-1 in humans depend on interaction with the GLP-1 receptor

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Counterregulatory responses to postprandial hypoglycemia after Roux-en-Y gastric bypass

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Fractionated free fatty acids and their relation to diabetes status after Roux-en-Y gastric bypass: A cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Individuals with obesity due to pathogenic heterozygous melanocortin 4 receptor (MC4R) mutations can be treated efficiently with the glucagon-like peptide-1 receptor agonist (GLP-1 RA) liraglutide. Here, we report the effect of 16 weeks of liraglutide 3 mg/day treatment in a woman with morbid obesity and type 2 diabetes (T2D) due to homozygous pathogenic MC4R mutation. The body weight loss was 9.7 kg, similar to weight loss in heterozygous MC4R mutation carriers and common obesity. In addition, the treatment led to clinically relevant decreases in fasting glucose, triglycerides, systolic blood pressure, and normalization of glucose tolerance. We conclude that liraglutide reduces body weight and blood glucose levels in hetero- and homozygous MC4R mutation carriers. This serves as proof-of-concept that MC4Rs are not required for the body weight and glucose lowering effects of GLP-1 RAs and that liraglutide may be used as part of the treatment of obesity and T2D due to MC4R mutations.

OriginalsprogEngelsk
TidsskriftCell Reports
Vol/bind1
Udgave nummer1
Sider (fra-til)100006
DOI
StatusUdgivet - 21 apr. 2020

Bibliografisk note

© 2020.

ID: 61308830